D’OXYVA significantly enhances test results & clinical outcomes in 4-8 weeks, especially in combination with any other modality or diagnostics system as demonstrated in various treatment programs.
D’OXYVA® (deoxyhemoglobin vasodilator) biotechnology provides an inexpensive and simple method of solving the longstanding problem of delivering medication to the bloodstream through needles, which are highly invasive, or oral delivery, which often results in gastrointestinal (GI) tract absorption issues and loss of most of the active ingredients in medication.